<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Emerg Infect Dis</journal-id>
      <journal-id journal-id-type="publisher-id">EID</journal-id>
      <journal-title-group>
        <journal-title>Emerging Infectious Diseases</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1080-6040</issn>
      <issn pub-type="epub">1080-6059</issn>
      <publisher>
        <publisher-name>Centers for Disease Control and Prevention</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">22261434</article-id>
      <article-id pub-id-type="pmc">3310108</article-id>
      <article-id pub-id-type="publisher-id">11-0751</article-id>
      <article-id pub-id-type="doi">10.3201/eid1801.110751</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Letters to the Editor</subject>
        </subj-group>
        <subj-group subj-group-type="article-type">
          <subject>Letter</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title><italic>Mycobacterium riyadhense</italic> Pulmonary Infection, France and Bahrain</article-title>
        <alt-title alt-title-type="running-head"><italic>M. riyadhense</italic> Pulmonary Infection</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Godreuil</surname>
            <given-names>Sylvain</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Marchandin</surname>
            <given-names>H&#xE9;l&#xE8;ne</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Michon</surname>
            <given-names>Anne-Laure</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ponsada</surname>
            <given-names>Mikael</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Chyderiotis</surname>
            <given-names>Georges</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Brisou</surname>
            <given-names>Patrick</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bhat</surname>
            <given-names>Abdul</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Panteix</surname>
            <given-names>Gilles</given-names>
          </name>
        </contrib>
        <aff id="aff1">Institut National de la Sant&#xE9; et de la Recherche M&#xE9;dicale Unit&#xE9; 1058, Montpellier, France (S. Godreuil);</aff>
        <aff id="aff2">H&#xF4;pital Arnaud de Villeneuve, Montpellier (S. Godreuil, H. Marchandin, A.-L. Michon);</aff>
        <aff id="aff3">Universit&#xE9; Montpellier 1, Montpellier (H. Marchandin, A.-L. Michon);</aff>
        <aff id="aff4">Laboratoire Biomnis, Lyon, France (M. Ponsada, G. Chyderiotis, G. Panteix);</aff>
        <aff id="aff5">H&#xF4;pital d'Instruction des Arm&#xE9;es Sainte-Anne, Toulon, France (P. Brisou);</aff>
        <aff id="aff6">Awali Hospital, Awali, Bahrain (A. Bhat)</aff>
      </contrib-group>
      <author-notes>
        <corresp id="cor1">Address for correspondence: Sylvain Godreuil, Centre Hospitalo-Universitaire, H&#xF4;pital Arnaude Villeneuve, Laboratoire de Bact&#xE9;riologie 371, Avenue du Doyen Gaston Giraud, Montpellier Cedex 5 34295, France; email: <email xlink:href="godreuil@yahoo.fr">godreuil@yahoo.fr</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>1</month>
        <year>2012</year>
      </pub-date>
      <volume>18</volume>
      <issue>1</issue>
      <fpage>176</fpage>
      <lpage>178</lpage>
      <kwd-group kwd-group-type="author">
        <title>Keywords: </title>
        <kwd>non-tuberculous mycobacterium</kwd>
        <kwd>tuberculosis and other mycobacteria</kwd>
        <kwd>bacteria</kwd>
        <kwd>pulmonary infection</kwd>
        <kwd>emerging pathogen</kwd>
        <kwd>France</kwd>
        <kwd>Bahrain</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <p><bold>To the Editor:</bold>
<italic>Mycobacterium riyadhense</italic> is a newly described mycobacterial species that is potentially pathogenic for humans. Extrapulmonary infection with this nontuberculous mycobacterium (NTM) has been reported (<xref ref-type="bibr" rid="R1"><italic>1</italic></xref>).We report 2 cases of pulmonary infection with this NTM.</p>
    <p>The first case of infection was in a 39-year-old woman who was admitted to Toulon Military Hospital, Toulon, France, in December 2005 with suspected pulmonary tuberculosis. For 1 month, the patient had a persistent cough, fever, asthenia, and weight loss. Findings on chest radiographs were suggestive of tuberculosis, with cavitation in the right upper lobe, and the tuberculin skin test reaction was positive. Sputum specimens collected on 3 consecutive days were negative for acid-fast bacilli (AFB), but broth cultures (BacT/ALERT 3D system; bioM&#xE9;rieux, Marcy l&#x2019;Etoile, France) yielded mycobacterial growth.</p>
    <p>We used 4 multiplex line-probe assays to identify the mycobacteria: GenoType MTBC (Hain Lifescience, Nehren, Germany) identified the organisms as members of the <italic>M. tuberculosis</italic> complex (MTBC; with a nonspecific reaction, banding pattern 1, 2, 3); GenoType Mycobacterium CM (Common Mycobacteria) (Hain Lifescience) kit and GenoType Mycobacterium AS (Additional Species) (Hain Lifescience) kit identified the strains as members of the MTBC and as unspecified <italic>Mycobacterium</italic> species, respectively; and INNO-LiPA MYCOBACTERIA v2 (Innogenetics, Ghent, Belgium) yielded a <italic>Mycobacterium</italic>-positive reaction by genus probe but no species-specific result.</p>
    <p>Following the criteria of the American Thoracic Society, we considered the isolates as the pathogens responsible for the patient&#x2019;s respiratory disease (<xref ref-type="bibr" rid="R2"><italic>2</italic></xref>). The patient was treated with a combination of isoniazid (INH), rifampin (RIF), ethambutol (EMB), and pyrazinamide (PZA). EMB and PZA were continued for 2 months; INH and RIF were continued for 10 months (<xref ref-type="table" rid="T1">Table</xref>), at which time the patient was considered cured.</p>
    <table-wrap id="T1" position="float">
      <label>Table</label>
      <caption>
        <title>Clinical characteristics, drug susceptibility testing, and outcome for 3 case-patients with <italic>Mycobacterium riyadhense</italic> infection, France and Bahrain*</title>
      </caption>
      <table frame="hsides" rules="groups">
        <col width="34" span="1"/>
        <col width="52" span="1"/>
        <col width="54" span="1"/>
        <col width="63" span="1"/>
        <col width="60" span="1"/>
        <col width="117" span="1"/>
        <col width="58" span="1"/>
        <col width="43" span="1"/>
        <thead>
          <tr>
            <th rowspan="2" valign="bottom" align="left" scope="col" colspan="1">Patient age, y/sex</th>
            <th rowspan="2" valign="bottom" align="center" scope="col" colspan="1">Clinical situation</th>
            <th valign="bottom" colspan="3" align="center" scope="colgroup" rowspan="1">Molecular-based identification of <italic>M. riyadhense</italic><hr/></th>
            <th rowspan="2" valign="bottom" align="center" scope="col" colspan="1">Drug susceptibility pattern, drug (MIC, &#xB5;g/mL) interpretation</th>
            <th rowspan="2" valign="bottom" align="center" scope="col" colspan="1">Antimicrobial drug therapy</th>
            <th rowspan="2" valign="bottom" align="center" scope="col" colspan="1">Treatment duration, outcome</th>
          </tr>
          <tr>
            <th valign="bottom" colspan="1" align="center" scope="colgroup" rowspan="1">Gene</th>
            <th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">% Sequence similarity with type strain</th>
            <th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">GenBank accession nos.</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td valign="top" align="left" scope="row" rowspan="1" colspan="1">19/M&#x2020;<hr/></td>
            <td valign="top" align="center" rowspan="1" colspan="1">Bone infection in left maxillary sinus<hr/></td>
            <td valign="top" align="center" rowspan="1" colspan="1">16S rRNA, <italic>rpoB</italic>, <italic>hsp65</italic><hr/></td>
            <td valign="top" align="center" rowspan="1" colspan="1">Type strain<hr/></td>
            <td valign="top" align="center" rowspan="1" colspan="1">EU27464, FJ786256, EU921671<hr/></td>
            <td valign="top" align="center" rowspan="1" colspan="1">AMK (10.0) R; CYC (20.0) S; CIP (2.0) S; CLF (&lt;0.5) S; CLR (&lt;2.0) S; EMB (5.0) S; INH (1.0) I; PAS (&gt;1.0) R; PRO (&lt;1.0) S; RFB (0.2) S; RIF (0.2) S; STR (5.0) S&#x2021;<hr/></td>
            <td valign="top" align="center" rowspan="1" colspan="1">INH, RFP, EMB; then INH, RFP<hr/></td>
            <td valign="top" align="center" rowspan="1" colspan="1">9 mo, cured<hr/></td>
          </tr>
          <tr>
            <td valign="top" align="left" scope="row" rowspan="1" colspan="1">39/F&#xA7;<hr/></td>
            <td valign="top" align="center" rowspan="1" colspan="1">Pulmonary infection<hr/></td>
            <td valign="top" align="center" rowspan="1" colspan="1">16S rRNA&#xB6;, <italic>rpoB</italic>, <italic>hsp65</italic><hr/></td>
            <td valign="top" align="center" rowspan="1" colspan="1">99.8, 99.8, 100<hr/></td>
            <td valign="top" align="center" rowspan="1" colspan="1">JF896094, JF896096, JF896098<hr/></td>
            <td valign="top" align="center" rowspan="1" colspan="1">AMK (<underline>&lt;</underline>1.0) S; CIP (1.0) S; CLR (0.12) S; DOX (16.0) R; EMB (<underline>&lt;</underline>0.5) S; ETH (0.3) S; INH (0.5) S; LZD (<underline>&lt;</underline>1.0) S; MOX (<underline>&lt;</underline>0.12) S; RFB (<underline>&lt;</underline>0.25) S; RIF (<underline>&lt;</underline>0.12) S; STR (1.0) S; TMP/SMX (<underline>&lt;</underline>0.12/2.38) NA#<hr/></td>
            <td valign="top" align="center" rowspan="1" colspan="1">INH, RFP, EMB, PZA; then INH, RFP<hr/></td>
            <td valign="top" align="center" rowspan="1" colspan="1">1 y, cured<hr/></td>
          </tr>
          <tr>
            <td valign="top" align="left" scope="row" rowspan="1" colspan="1">43/M**</td>
            <td valign="top" align="center" rowspan="1" colspan="1">Pulmonary infection</td>
            <td valign="top" align="center" rowspan="1" colspan="1">16S rRNA&#xB6;, <italic>rpoB</italic>, <italic>hsp65</italic></td>
            <td valign="top" align="center" rowspan="1" colspan="1">99.8, 99.7, 99.1</td>
            <td valign="top" align="center" rowspan="1" colspan="1">JF896095, JF896097, JF896099</td>
            <td valign="top" align="center" rowspan="1" colspan="1">AMK (<underline>&lt;</underline>1.0) S; CIP (0.12) S; CLR (0.12) S; EMB (<underline>&lt;</underline>0.5) S; ETH (0.3) S; DOX (4.0) R; INH (0.25) S; LZD (<underline>&lt;</underline>1.0) S; MOX (<underline>&lt;</underline>0.12) S; RFB (<underline>&lt;</underline>0.25) S; RIF (<underline>&lt;</underline>0.12) S; STR (<underline>&lt;</underline>0.5) S; TMP/SMX (<underline>&lt;</underline>2.0/38.0) NA#</td>
            <td valign="top" align="center" rowspan="1" colspan="1">CLR, CIP; then INH, RFP, EMB, PZA, CLR, CIP; then INH, RFP, CLR, CIP</td>
            <td valign="top" align="center" rowspan="1" colspan="1">1 y, relapse; 8 mo, cured</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <p>*AMK, amikacin; R, resistant; CYC, cycloserine; S, susceptible; CIP, ciprofloxacin; CLF, clofazimine; CLR, clarithromycin; EMB, ethambutol; INH, isoniazid; I, intermediate; PAS, para-aminosalicylate sodium; PRO, prothionamide; RFB, rifabutin; RIF, rifampin; STR, streptomycin ; RFP, rifapentine; DOX, doxycycline; ETH, ethionamide; LZD, linezolid; MOX, moxifloxacin; TMP/SMX, trimethoprim/sulfamethoxazole; NA, not available; PZA, pyrazinamide.&#x2028;&#x2020;Patient in Saudi Arabia; reported by van Ingen et al. (<xref ref-type="bibr" rid="R1"><italic>1</italic></xref>).&#x2028;&#x2021;Drug susceptibility testing was performed by using the agar dilution method.&#x2028;&#xA7;Patient in France.&#x2028;&#xB6;Low 16S rRNA gene polymorphism between several mycobacterial species.&#x2028;#Drug susceptibility testing was performed by using broth microdilution panels (SLOMYCO Sensititer; Trek Diagnosis Systems, Cleveland&lt; OH, USA) and interpreted according to standards of the National Committee for Clinical Laboratory Standards (<xref ref-type="bibr" rid="R3"><italic>3</italic></xref>).&#x2028;**Patient in Bahrain.</p>
      </table-wrap-foot>
    </table-wrap>
    <p>The second case of infection was in a 43-year-old man who was admitted to Awali Hospital, Awali, Bahrain, in November 2006. The patient reported malaise, insomnia, cough, weight loss, and anorexia. Radiographs showed features suggestive of tuberculosis (left upper lobe consolidation with focal cavitation). Sputum specimens collected on 3 consecutive days were positive for AFB and mycobacterial growth. To identify the pathogen(s), we used the same 4 mutiplex line-probe assays as used for case-patient 1, and results were similar. The identified strain was considered to be the pathogen responsible for the respiratory disease (<xref ref-type="bibr" rid="R2"><italic>2</italic></xref>).</p>
    <p>The patient was treated with a combination of clarithromycin (CLR) and ciprofloxacin (CIP) for 12 months; however, he had a clinical and microbiological (i.e., positive for AFB and culture results with the same NTM) relapse during this treatment. In November 2007, 3 sputum specimens from the patient were positive for AFB, and cultures yielded a mycobacterial strain identical to that identified by the assays. The patient was treated with antituberculous drugs (INH, RIF, EMB, PZA, plus CLR and CIP) for 6 months, and then INH, RIF, CLR, CIP were continued for 2 additional months (<xref ref-type="table" rid="T1">Table</xref>), after which the patient showed clinical improvement.</p>
    <p>In the 2 cases, molecular identification of the isolates as <italic>M. riyadhense</italic> was achieved by using partial <italic>hsp65</italic> and <italic>rpoB</italic> gene sequencing, which was based on the high level of sequence identities with the type strain of <italic>M. riyadhense</italic> and a distance score of 3.5 and 4.6, respectively, to the next species, &#x201C;<italic>M. simulans</italic>&#x201D; (<xref ref-type="table" rid="T1">Table</xref>). Broth microdilution panels (SLOMYCO Sensititer; Trek Diagnosis Systems, Cleveland, OH, USA) were used to determine drug susceptibility (<xref ref-type="table" rid="T1">Table</xref>) (<xref ref-type="bibr" rid="R3"><italic>3</italic></xref>).</p>
    <p>Commercial probes are frequently used for rapid identification of mycobacterial species (<xref ref-type="bibr" rid="R4"><italic>4</italic></xref>); however, <italic>M. riyadhense</italic> and other recently proposed NTMs (e.g., <italic>M. kumamotonense</italic> and &#x201C;<italic>M. simulans</italic>&#x201D;) cross-react with MTBC DNA probes and may be missed by line-probe assays (<xref ref-type="bibr" rid="R5"><italic>5</italic></xref><italic>,</italic><xref ref-type="bibr" rid="R6"><italic>6</italic></xref>). With the emergence of new NTM species, commercial probes could fail to discriminate between species, leaving clinical isolates either unidentified or misidentified. Because of its ease of use, accuracy, and discriminatory power, multilocus sequence analysis may soon become the standard for routine NTM species identification.</p>
    <p>We have shown evidence for the pathogenic role of <italic>M. riyadhense</italic> in pulmonary diseases, a pathogen that has previously been reported to have extrapulmonary pathogenicity (<xref ref-type="bibr" rid="R1"><italic>1</italic></xref>). Clinical and radiologic signs and symptoms of pulmonary infection caused by <italic>M. riyadhense</italic>, including cough, weight loss, fever, and cavitating lung lesions, were similar to those in typical cases caused by MTBC strains. van Ingen et al. (<xref ref-type="bibr" rid="R7"><italic>7</italic></xref>) suggested that the region of difference 1 (RD1) virulence locus identified in MTBC members may also play a crucial role in virulence of some NTM species. These authors found RD1 genes in NTMs that were causing human disease, including <italic>M. kansasii</italic>, <italic>M. szulgai</italic>, <italic>M. marinum</italic>, and the type strain of <italic>M. riyadhense</italic> (<xref ref-type="bibr" rid="R7"><italic>7</italic></xref>).</p>
    <p>We confirmed the presence of RD1 <italic>esat-6</italic> and <italic>cfp-10</italic> genes in the <italic>M. riyadhense</italic> isolates reported here (GenBank accession nos. JF896090&#x2013;JF896093). Because <italic>M. riyadhense</italic> is an emerging pathogen with, to our knowledge, only 1 previously reported extrapulmonary case of infection (<xref ref-type="bibr" rid="R1"><italic>1</italic></xref>), the optimal treatment for infected patients is unknown. Our results and drug susceptibility testing indicate that antituberculous drugs, including INH, RMP, and EMB, are effective against <italic>M. riyadhense</italic> infection (<xref ref-type="table" rid="T1">Table</xref>), but the combination of CLR plus CIP was not effective in 1 case-patient reported here, despite in vitro susceptibility to both drugs.</p>
  </body>
  <back>
    <fn-group>
      <fn fn-type="citation">
        <p><italic>Suggested citation for this article</italic>: Godreuil S, Marchandin H, Michon A-L, Ponsada M, Chyderiotis G, Brisou P, et al. <italic>Mycobacterium riyadhense</italic> pulmonary infection, France and Bahrain [letter]. Emerg Infect Dis [serial on the Internet]. 2012 Jan [<italic>date cited</italic>]. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3201/eid1801.110751">http://dx.doi.org/10.3201/eid1801.110751</ext-link></p>
      </fn>
    </fn-group>
    <ack>
      <title>Acknowledgments</title>
      <p>We thank Isabelle Zorgniotti and Dominique Terru for excellent technical assistance and Laurent Lefran&#xE7;ois and the staff of the international department of Biomnis for performing laboratory tests.</p>
      <p>The Institut de Recherche pour le D&#xE9;veloppement, Centre National de la Recherche Scientifique, and H&#xF4;pital Arnaud de Villeneuve provided financial and technical support.</p>
    </ack>
    <ref-list>
      <title>References</title>
      <ref id="R1">
        <label>1. </label>
        <mixed-citation publication-type="journal"><string-name><surname>van Ingen</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Al-Hajoj</surname>
<given-names>SA</given-names></string-name>, <string-name><surname>Boeree</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Al-Rabiah</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Enaimi</surname>
<given-names>M</given-names></string-name>, <string-name><surname>de Zwaan</surname>
<given-names>R</given-names></string-name>, <etal/>
<article-title><italic>Mycobacterium riyadhense</italic> sp. nov., a non-tuberculous species identified as <italic>Mycobacterium tuberculosis</italic> complex by a commercial line-probe assay.</article-title>
<source>Int J Syst Evol Microbiol</source>. <year>2009</year>;<volume>59</volume>:<fpage>1049</fpage>&#x2013;<lpage>53</lpage>
<pub-id pub-id-type="doi">10.1099/ijs.0.005629-0</pub-id><pub-id pub-id-type="pmid">19406791</pub-id></mixed-citation>
      </ref>
      <ref id="R2">
        <label>2. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Griffith</surname>
<given-names>DE</given-names></string-name>, <string-name><surname>Aksamit</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Brown-Elliott</surname>
<given-names>BA</given-names></string-name>, <string-name><surname>Catanzaro</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Daley</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Gordin</surname>
<given-names>F</given-names></string-name>, <etal/>
<article-title>An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.</article-title>
<comment>[Erratum in Am J Respir Crit Care Med. 2007;175] [7]</comment>:744-5. <source>Am J Respir Crit Care Med</source>. <year>2007</year>;<volume>175</volume>:<fpage>367</fpage>&#x2013;<lpage>416</lpage>
<pub-id pub-id-type="doi">10.1164/rccm.200604-571ST</pub-id><pub-id pub-id-type="pmid">17277290</pub-id></mixed-citation>
      </ref>
      <ref id="R3">
        <label>3. </label>
        <mixed-citation publication-type="book"><collab>National Committee for Clinical Laboratory Standards</collab> Susceptibility testing of mycobacteria, <italic>Nocardiae</italic>, and other aerobic actinomycetes; approved standard. NCCLS document M24-A. Wayne (PA): The Committee; <year>2003</year></mixed-citation>
      </ref>
      <ref id="R4">
        <label>4. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Tortoli</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Nanetti</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Piersimoni</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Cichero</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Farina</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Mucignat</surname>
<given-names>G</given-names></string-name>, <etal/>
<article-title>Performance assessment of new multiplex probe assay for identification of mycobacteria.</article-title>
<source>J Clin Microbiol</source>. <year>2001</year>;<volume>39</volume>:<fpage>1079</fpage>&#x2013;<lpage>84</lpage>
<pub-id pub-id-type="doi">10.1128/JCM.39.3.1079-1084.2001</pub-id><pub-id pub-id-type="pmid">11230430</pub-id></mixed-citation>
      </ref>
      <ref id="R5">
        <label>5. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Rodriquez-Aranda</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Jimenez</surname>
<given-names>MS</given-names></string-name>, <string-name><surname>Yubero</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Chaves</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Rubio-Garcia</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Palenque</surname>
<given-names>E</given-names></string-name>, <etal/>
<article-title>Misidentification of <italic>Mycobacterium kumamotonense</italic> as <italic>M. tuberculosis.</italic></article-title>
<source>Emerg Infect Dis</source>. <year>2010</year>;<volume>16</volume>:<fpage>1178</fpage>&#x2013;<lpage>80</lpage><pub-id pub-id-type="pmid">20587204</pub-id></mixed-citation>
      </ref>
      <ref id="R6">
        <label>6. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Tortoli</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Rogasi</surname>
<given-names>PG</given-names></string-name>, <string-name><surname>Fantoni</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Beltrami</surname>
<given-names>C</given-names></string-name>, <string-name><surname>De Francisci</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Mariottini</surname>
<given-names>A</given-names></string-name>
<article-title>Infection due to a novel mycobacterium, mimicking multidrug-resistant <italic>Mycobacterium tuberculosis.</italic></article-title>
<source>Clin Microbiol Infect</source>. <year>2010</year>;<volume>16</volume>:<fpage>1130</fpage>&#x2013;<lpage>4</lpage>
<pub-id pub-id-type="doi">10.1111/j.1469-0691.2009.03063.x</pub-id><pub-id pub-id-type="pmid">19832722</pub-id></mixed-citation>
      </ref>
      <ref id="R7">
        <label>7. </label>
        <mixed-citation publication-type="journal"><string-name><surname>van Ingen</surname>
<given-names>J</given-names></string-name>, <string-name><surname>de Zwaan</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Dekhuijzen</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Boeree</surname>
<given-names>M</given-names></string-name>, <string-name><surname>van Soolingen</surname>
<given-names>D</given-names></string-name>
<article-title>Region of difference 1 in nontuberculous <italic>Mycobacterium</italic> species adds a phylogenetic and taxonomical character.</article-title>
<source>J Bacteriol</source>. <year>2009</year>;<volume>191</volume>:<fpage>5865</fpage>&#x2013;<lpage>7</lpage>
<pub-id pub-id-type="doi">10.1128/JB.00683-09</pub-id><pub-id pub-id-type="pmid">19617365</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
